These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15131024)

  • 1. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
    Giles F; Thomas D; Garcia-Manero G; Faderl S; Cortes J; Verstovsek S; Ferrajoli A; Jeha S; Beran M; Koller C; Andreeff M; Cahill A; Clairmont C; Sznol M; Kantarjian H
    Clin Cancer Res; 2004 May; 10(9):2908-17. PubMed ID: 15131024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
    Murren J; Modiano M; Kummar S; Clairmont C; Egorin M; Chu E; Sznol M
    Invest New Drugs; 2005 Mar; 23(2):123-35. PubMed ID: 15744588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
    Giles F; Verstovsek S; Faderl S; Vey N; Karp J; Roboz G; Khan KD; Cooper M; Bilgrami SF; Ferrant A; Daenen S; Karsten V; Cahill A; Albitar M; Kantarjian H; O'Brien S; Feldman E
    Leuk Res; 2006 Dec; 30(12):1591-5. PubMed ID: 16574225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
    Cortes J; Faderl S; Estey E; Kurzrock R; Thomas D; Beran M; Garcia-Manero G; Ferrajoli A; Giles F; Koller C; O'Brien S; Wright J; Bai SA; Kantarjian H
    J Clin Oncol; 2005 Apr; 23(12):2805-12. PubMed ID: 15728224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
    Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
    Gururangan S; Turner CD; Stewart CF; O'Shaughnessy M; Kocak M; Poussaint TY; Phillips PC; Goldman S; Packer R; Pollack IF; Blaney SM; Karsten V; Gerson SL; Boyett JM; Friedman HS; Kun LE
    Clin Cancer Res; 2008 Feb; 14(4):1124-30. PubMed ID: 18281546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
    J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
    Yee KW; Hagey A; Verstovsek S; Cortes J; Garcia-Manero G; O'Brien SM; Faderl S; Thomas D; Wierda W; Kornblau S; Ferrajoli A; Albitar M; McKeegan E; Grimm DR; Mueller T; Holley-Shanks RR; Sahelijo L; Gordon GB; Kantarjian HM; Giles FJ
    Clin Cancer Res; 2005 Sep; 11(18):6615-24. PubMed ID: 16166440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
    Gore SD; Weng LJ; Zhai S; Figg WD; Donehower RC; Dover GJ; Grever M; Griffin CA; Grochow LB; Rowinsky EK; Zabalena Y; Hawkins AL; Burks K; Miller CB
    Clin Cancer Res; 2001 Aug; 7(8):2330-9. PubMed ID: 11489809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
    Roboz GJ; Khoury HJ; Jabbour E; Session W; Ritchie EK; Miao H; Faderl S; Zheng W; Feldman EJ; Arellano M; Morrison JG; Ravandi F
    Leuk Lymphoma; 2015 Feb; 56(2):395-400. PubMed ID: 24794806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.